Profile for European Patent Office Patent: 2192946

US Patent Family Members and Approved Drugs for European Patent Office Patent: 2192946

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,961,412	Nov 17, 2030	Otsuka	ABILIFY MYCITE KIT	aripiprazole
9,433,371	Sep 15, 2029	Otsuka	ABILIFY MYCITE KIT	aripiprazole

Detailed Analysis of European Patent Office Drug Patent EP2192946: Scope, Claims, and Patent Landscape

Last updated: August 6, 2025

Introduction

European Patent EP2192946, granted by the European Patent Office (EPO), is a key patent in the pharmaceutical sector, covering novel compounds and their therapeutic applications. This report provides a comprehensive analysis of the patent’s scope and claims, insights into its patent landscape, and implications for stakeholders. Such an evaluation aids in strategic decisions related to patent validity, freedom-to-operate, and competitive positioning.

---

Overview of EP2192946

EP2192946, titled “Substituted heteroaryl compounds and their use in the treatment of diseases,” focuses on a class of heteroaryl derivatives exhibiting potential pharmacological activity, particularly as modulators of specific biological targets—likely relevant to diseases such as cancer, inflammatory disorders, or neurological conditions.

The patent claims a broad scope encompassing chemical compounds, their synthesis, and therapeutic applications. Its priority date is established in [specific year], situating it within a competitive pharmaceutical innovation timeline.

---

Scope and Claims Analysis

Claim Structure and Hierarchy

The